Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Treatments in the Oligometastatic Setting: A Secondary Analysis of the SABR-COMET Randomized Trial
Abstract
PURPOSE
Randomized data assessing the longitudinal quality of life (QoL) impact of SABR in the oligometastatic setting are lacking.
METHODS AND MATERIALS
We enrolled patients who had a controlled primary malignancy with 1-5 metastatic lesions, with good performance status and life expectancy >6 months. We randomized in a 1:2 ratio between standard of care (SOC) treatment [SOC Arm] vs. SOC plus SABR to all metastatic lesions [SABR Arm]. QoL was measured using the Functional Assessment of Cancer Therapy - General (FACT-G). QoL changes over time and between groups was assessed with linear mixed modeling.
RESULTS
Ninety-nine patients were randomized. Median age was 68 (range: 43-89) and 60% were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18) and prostate (n=16). Most patients (n=92) had 1-3 metastases. Median follow-up was 26 months. Because of the previously-reported inferior survival of the SOC arm, the time for attrition in QOL respondents to <10% of subjects was shorter in the SOC vs SABR arm (30 vs. 42 months). In the whole cohort, QoL declined over time after randomization: there were significant declines in total FACT-G score over time compared to baseline (p<0.001), due to declines in physical and functional subscales (both p<0.001), with no declines in social and emotional subscales. However, the magnitudes of decline were small, and CMCs were not seen at most time points. Comparison between arms showed no differences in QoL…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 92 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.